Design, Synthesis, and Biological Evaluation of Novel P2X7 Receptor Antagonists for the Treatment of Septic Acute Kidney Injury
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Ruijia Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Sepsis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Sichuan University, Department of Science and Technology of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Sepsis-associated acute kidney injury (AKI) is a serious clinical problem, without effective drugs. Abnormal activation of the purinergic P2X7 receptor (P2X7R) in septic kidneys makes its antagonist a promising therapeutic approach. Herein, a series of novel P2X7R antagonists were designed, synthesized, and structurally optimized. Based on in vitro potency in human/mouse P2X7R using HEK293 cells, hepatic microsomal stability, and pharmacokinetic and preliminary in vivo assessments, compound 14a was identified by respective human and mouse P2X7R IC50 values of 64.7 and 10.1 nM, together with favorable pharmacokinetic properties. Importantly, 14a dose-dependently alleviated kidney dysfunction and pathological injury in both lipopolysaccharide (LPS)- and cecal ligation/perforation (CLP)-induced septic AKI mice with a good safety profile. Mechanistically, 14a could suppress NLRP3 inflammasome activation to inhibit the expression of cleaved caspase-1, gasdermin D, IL-1β, and IL-18 in the injured kidneys of septic mice. Collectively, these results highlighted that P2X7R antagonist 14a exerted a therapeutic potential against septic AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- Division of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu 610041, China.
- Laboratory of Metabolomics and Drug-induced Liver Injury, Department of Gastroenterology & Hepatology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610…
- Division of Thyroid Surgery, Department of General Surgery and Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chen…
Förderung
- Sichuan University
- Department of Science and Technology of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, R., Su, K., Yang, L., Tang, M., Zhao, M., Ye, N., Cai, X., Jiang, X., Li, N., Peng, J., Zhang, X., Wang, B., Wu, W., Ma, L., & Ye, H. (2023). Design, Synthesis, and Biological Evaluation of Novel P2X7 Receptor Antagonists for the Treatment of Septic Acute Kidney Injury. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00837
Vancouver
Zhang R, Su K, Yang L, Tang M, Zhao M, Ye N, et al. Design, Synthesis, and Biological Evaluation of Novel P2X7 Receptor Antagonists for the Treatment of Septic Acute Kidney Injury. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00837
BibTeX
@article{Zhang2023,
author = {Zhang, Ruijia and Su, Kaiyue and Yang, Letian and Tang, Minghai and Zhao, Min and Ye, Neng and Cai, Xiaoying and Jiang, Xueqin and Li, Na and Peng, Jing and Zhang, Xinlu and Wang, Bo and Wu, Wenshuang and Ma, Liang and Ye, Haoyu},
title = {Design, Synthesis, and Biological Evaluation of Novel P2X7 Receptor Antagonists for the Treatment of Septic Acute Kidney Injury},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00837}
}
EUVIMED